Colchicine and Inflammation in Aortic Stenosis (CHIANTI)
Does Colchicine Reduce Progression of Aortic Valve Stenosis?
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
The Netherlands
-
Nijmegen, The Netherlands, Netherlands
- Radboudumc
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criterion:
• Asymptomatic moderate aortic valve stenosis on recent (<6 months) echocardiography (based on peak velocity, mean gradient, aortic valve area). The severity of AS will be quantified according to current EACVI / ASE guidelines.
Exclusion Criteria:
- Heavily calcified aortic valve on echocardiography (defined as grade 4 calcification: extensive thickening/calcification of all cusps as described in the articles by Rosenhek et al.);
- a planned aortic valve replacement in the next six months;
- severe mitral valve stenosis (MVA < 1cm2);
- severe mitral or aortic valve regurgitation;
- rheumatic aortic valve disease;
- bicuspid aortic valve;
- valvular disease due to history of chest radiation;
- left ventricular dysfunction (LVEF < 35%);
- renal impairment (eGFR <30 ml/min/1.73m2);
- patients aged <50 and >80 years;
- pre-existing chronic gastro-intestinal complaints which may obscure signs of colchicine intolerance;
- child-bearing potential without the use of contraception;
- use of CYP3A4 (e.g. verapamil) or P-glycoprotein inhibitors;
- use of bisphosphonate or denosumab;
- chronic use of immunosuppressants or anti-inflammatory drugs including colchicine and NSAID's (excl. acetylsalicylic acid);
- active or chronic liver disease;
- the presence of a pacemaker or internal cardiac defibrillator;
- life expectancy <2 years.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Colchicine
75 patients will receive colchicine tablets
|
ATC: M04AC01
|
|
Placebo Comparator: Placebo
75 patients will receive placebo tablets
|
Placebo tablets
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in aortic valve calcium score
Time Frame: Baseline and 24 months
|
Change in aortic valve calcium score measured by computed tomography aortic valve calcification (CT-AVC).
|
Baseline and 24 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Aortic valve 18F-NaF uptake
Time Frame: Baseline and 24 months
|
Difference in aortic valve 18F-NaF uptake of the aortic valve using positron emission tomography (PET) between baseline and end of study.
|
Baseline and 24 months
|
|
Change in echocardiographic parameter for aortic stenosis
Time Frame: Baseline, 12 months and 24 months
|
Determined by change in peak velocity (m/s)
|
Baseline, 12 months and 24 months
|
|
Adverse Outcomes
Time Frame: Baseline and 24 months
|
Determine the effect of colchicine on calcified aortic stenosis related adverse outcomes (cardiac death, myocardial infarction, stroke, (hospitalization for) heart failure and aortic valve replacement).
|
Baseline and 24 months
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Heart Diseases
- Metabolic Diseases
- Heart Valve Diseases
- Ventricular Outflow Obstruction
- Calcium Metabolism Disorders
- Pathological Conditions, Signs and Symptoms
- Nutritional and Metabolic Diseases
- Aortic Valve Disease
- Aortic Valve Stenosis
- Cardiovascular Diseases
- Inflammation
- Calcinosis
- Aortic Valve, Calcification of
- Heterocyclic Compounds
- Alkaloids
- Colchicine
Other Study ID Numbers
Other Study ID Numbers
- 112719
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.